Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study

Published:2020-10-09 Issue:11 Volume:9 Page:628-638
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Grisic Ana‐Marija¹²³,Khandelwal Akash³,Bertolino Mauro³,Huisinga Wilhelm⁴,Girard Pascal⁵,Kloft Charlotte¹

Affiliation:

1. Department of Clinical Pharmacy and Biochemistry Institute of Pharmacy Freie Universitaet Berlin Berlin Germany

2. Graduate Research Training Program PharMetrX Berlin Germany

3. Merck KGaA Darmstadt Germany

4. Institute of Mathematics Universität Potsdam Potsdam Germany

5. Merck Institute of Pharmacometrics Merck Serono S.A. Lausanne Switzerland

Funder

Merck KGaA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12558

Reference24 articles.

1. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

2. Pharmacokinetics of Monoclonal Antibodies

3. World Health Organization: Latest global cancer data. (2018). Accessed November 7 2019.

4. Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

5. Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer;Clinical Pharmacology & Therapeutics;2024-08-12

2. Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients;British Journal of Clinical Pharmacology;2023-12-29

3. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

4. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

5. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients;Clinical Pharmacokinetics;2023-07-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3